fda semaglutide warning september 2025 Medscape | The has approved once-daily oral 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. ⁠ FDA sends warning letter to

Withdrawal symptoms can include Increased appetite Decreased satiety Elevated blood sugar levels Weight gain Elevated blood pressure and other cardiovascular changes A study from a 2022 clinical trial that tested semaglutide treatment for weight loss found that participants had regained about two-thirds of their initial weight loss on average, and many patients also experienced raised blood pressure levels

Many ingredients can also be prepped ahead of time, making it easier to build healthy meals that fit GLP-1 dietary guidelines even when your appetite is low

Understanding this connection helps patients and providers make informed decisions about treatment and hair health management

377:644-657 [PubMed: 28605608] 145

topical eflornithine for facial hirsutism (availability may vary) [16] [12] Fertility: Letrozole is generally preferred first-line for ovulation induction in specialist settings, with clomifene citrate as an alternative